Select Publications

Berry DA et al. HER2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive,node-positive breast cancer. J Clin Oncol 2000;18(20):3471-9. Abstract

Harvey JM et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17(5):1474-81. Abstract

Jubelirer SJ et al. Prognostic factors determining survival in breast cancer patients presenting with metastatic disease. W V Med J 1990;86(1):7-9. Abstract

Kunisue H et al. AntiHER2 antibody enhances the growth inhibitory effect of antioestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 2000;82(1):46-51. Abstract

Meier CR, Jick H.Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998;45(6):608-12. Abstract

Mouridsen H et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19(10):2596-606. Abstract

Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:Results of a North American multicenter randomized trial.Arimidex Study Group. J Clin Oncol 2000;18(22):3758-67. Abstract

Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer:Meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol 2001 Feb;28(1 Suppl 3):1-12. Abstract

Nicholson BP. Ongoing and planned trials of hormonal therapy and trastuzumab. Semin Oncol 2000;27(6 Suppl 11):33-7;discussion 92-100. Abstract

Piccart MJ et al. HER2:A ‘predictive factor ’ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36(14):1755-61. Abstract

Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors,with analysis of mortality from contralateral breast cancer,cardiovascular events,endometrial cancer and thromboembolic episodes. J Clin Oncol 1998;16(6):2018-24. Abstract

Schorn C et al.MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiology 1999;9:470-473. Abstract

Simon R et al. Patterns of HER2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93(15):1141-6. Abstract

Slamon DJ et al. Human breast cancer:Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987;235:177-182. Abstract

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract

Sonoo H et al. Predictive factors for response to endocrine therapy in patients with recurrent breast cancer. Breast Cancer 2000;7(4):297-301. Abstract

Sparano JA.Cardiac toxicity of trastuzumab (Herceptin):Implications for the design of adjuvant trials. Semin Oncol 2001;28(1 Suppl 3):20-7. Abstract

Vogel C et al. First-line,non-hormonal,treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized antiHER2 antibody). Proc ASCO 2000; Abstact 275.

Home · Search